The latest description of our device aims at addressing the largely unmet needs of patients troubled by brain tumors, by providing a high-throughput program for fast and reliable testing of novel ingredients (including biotechnology and nanotechnology therapeutic agents) across a realistic model of blood-brain barrier and in the presence of microtumors. The latter signify the foci that continue in the brain after tumor resection that typically give rise to tumor recurrences, and can be attained in vitro from the affected person cells through biopsies or after surgical interventions, thus offering personalized medications with better predictable result.
Simply by properly changing the 3D IMAGES cultures of cells to be magnetically docked to the luminal compartment of your device, the latter can provide a flexible platform applicable in the circumstance of head cancer remedy, as well as to other disorders impacting on the central nervous system (CNS, just like: Alzheimer’s disease, stroke, amyotrophic lateral sclerosis etc . ) that totally represent the 35% of all diseases in Europe exclusively and influence approximately 1 ) 5 billion people in the world.
This year, the total Western european costs of brain disorders were believed to be of 798 billion ¬, divided as follows: 37% health care costs, 23% immediate non-medical costs, and 40% indirect costs. Of these, a few. 2 billion ¬ had been spent to get brain malignancies, 13. 9 billion ¬ for Parkinson’s disease, sixty four. 1 billion dollars ¬ for stroke and 105. 2 billion ¬ for dementia. Brain disorders therefore present an enormous socioeconomic burden to Europe that individuals mean to alleviate with our gadget by increasing the getting of the most suited and safe candidate drugs pertaining to clinical trials and ad-hoc medicines.
The BBB version can be an excellent source of interest to numerous laboratories and clinics included worldwide in brain cancer treatment, and will ultimately benefit a huge number of patients battling for different CNS conditions. Making sure the project compliance with all the provisions of Directive 2010/63/EU concerning replacing animals with in vitro versions, our gadget will also lessen the number of pets or animals to be found in pre-clinical research, as well as costs for dog management. Furthermore, it will considerably contribute to lowering the risk of both equally early and late stage failures of drug tests in clinical trials, and thus to contrast the detected slowdown in medicine development to get CNS.
Evaluation and affirmation of the success of the project’s outcomes
We want to offer available a fluidic device with unprecedented bio mimicry features by which includes both healthful and disease compartments which have been micro- and nanostructured upon 3D, and thus to defeat limitations of existing solutions provided by opponents (please observe Table one particular for details).
Of the six technology already available, only several (from Flocel, Kirkstall Mimetas, and SynVivo) are active. Among these kinds of, only two (from Flocel and SynVivo) are optically transparent pertaining to real-time monitoring of the ethnicities, and only one particular (from Flocel) enables TEER measurement pertaining to quantification of BBB stringency. To date, the dynamic systems on the market permit the traditions of just two cellular typologies (astrocytes and endothelial cells).
With its remarkably reproducible fabrication, micro- and nanostructuring, multiple co-culturing functionality, optical visibility, predisposition to pulsatile circulation and TEER measurements and low cost, the device is definitely expected to very easily position in both the European and the global market, and outsmart competitors thanks to the progressive approach of culturing about three distinct cell types on 3 DIMENSIONAL.
IPR situation and approach
Towards the aim of creating a solid IPR position surrounding the emerging technology a systematic trail reports of experimental data will be made and will make the basis to get proprietary information. Based on this and in esteem on any kind of applicable prior art, researchers will work around the problem figuring out novelty and inventive step for submitting patent software based on the robust and reproducible technology. All the reports will have both strategies for architecture and for acceptance, with particular focus on artificial BBB strictness, rigor, harshness, inflexibility, rigidity, toughness and on permanent magnetic docking of microtumors. Jointly, know-how and any obvious application file will amount to viable components for a great out licensing strategy and the IP and/or the skills generated by the project will certainly eventually always be licensed out from IIT (licensor) to another party (licensee) for making, commercialization, and/or distribution with the device.
In this regard, shared exchange of know-how between licensor and licensee will probably be highly good for the final goal of making these devices promptly open to:
Understanding transfer technique
Potential licensees which were identified which have already provided a notification of interest to back up the BBBhybrid project happen to be Nanoscribe, Kayser Italia and Prodotti Gianni.
Nanoscribe is the singular manufacturer of the multiphoton program necessary to fabricate our system and it is accessible to provide machines to support it is production, as well as to offer technical support for expert-level users and to disseminate the results in the project to specialized stakeholders. For its eminent position available of high-precision additive manufacturing, for its limited interaction with research institutions and its significant involvement in research and development (RD) activities (30% of the personnel), Nanoscribe would represent the election licensee for manufacture and promo of our device.
Kayser Italia (KI) is a personal independent jetstream system anatomist company with 30-years long experience in design and fabrication of highly trustworthy fluidic gadgets for trials in tough conditions, including the low Globe orbit. KI has a worldwide leadership in assisting study to be performed onboard the International Space Station (ISS), and snugly collaborates together with the academia in RD, likewise funding a lot of graduate fellowships. KI was IIT spouse in the German Space Firm (ASI) Biomission “VITA” performed aboard the ISS with NASA support. KI can be bought to support the latest project by providing know-how inside the validation with the device during manufacturing and post-production, as well as commercialization/distribution of the same to interested stakeholders in both countrywide and international market.
Prodotti Gianni is a company with 70-years extended experience in distribution of pharmaceuticals and diagnostic assays, and, as an innovative firm, it spends an important amount of budget for new innovations (650, 000 ¬ in 2017). Prodotti Gianni provides collaboration agreements with several universities and research acadamies, and it is offered to provide capillary marketing and commercialization of our gadget on the nationwide market, likewise by diffusion of the technology at particular events.
